287 related articles for article (PubMed ID: 21680704)
1. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
3. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
[TBL] [Abstract][Full Text] [Related]
9. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
10. Emerging biological observations in prostate cancer.
Shah S; Small E
Expert Rev Anticancer Ther; 2010 Jan; 10(1):89-101. PubMed ID: 20014889
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
12. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
[TBL] [Abstract][Full Text] [Related]
13. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
Elife; 2016 May; 5():. PubMed ID: 27183006
[TBL] [Abstract][Full Text] [Related]
14. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
15. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
16. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
